CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.
UHKT-CAR19-01
Phase 1 other active
Quick answer
CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. for Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Modality
- other
- Status
- active